Tests diagnostiques et thérapies ciblées en cancérologie - Enjeux économiques

Patricia Marino; François Bertucci; Anthony Gonçalves; Valérie Seror

doi:10.1051/medsci/2012281s106

Accueil

Tous les numéros

Volume 28 (Mars 2012) Hors série n°1

Med Sci (Paris), 28 (2012) 19-23

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 28, Mars 2012 Génomique et recherche clinique en oncologie : approches de sciences humaines, économiques et sociales (SHES)


Page(s)		19 - 23
Section		M/S Revues
DOI		https://doi.org/10.1051/medsci/2012281s106
Publié en ligne		9 avril 2012

L’Horty Y, Quinet A, Rupprecht F. Expliquer la croissance des dépenses de santé : le rôle du niveau de vie et du progrès technique. Économie et Prévision 1997 ; 129–130 : 257–268. [Google Scholar]
Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011 ; 103 : 117–128. [CrossRef] [PubMed] [Google Scholar]
Situation de la chimiothérapie des cancers en 2010. Collection Rapports et synthèses. Boulogne-Billancourt : INCa, 2010. [Google Scholar]
Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 2009 ; 27 : 5868–5873. [CrossRef] [PubMed] [Google Scholar]
Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of Bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2009 ; 29 : 1247–1251. [CrossRef] [Google Scholar]
Hensley ML. Big costs for little gain in ovarian cancer. J Clin Oncol 2011 ; 29 : 1230–1232. [CrossRef] [PubMed] [Google Scholar]
Munro AJ, Niblock PG. Cancer research in the global village. Lancet 2010 ; 376 : 659–660. [CrossRef] [PubMed] [Google Scholar]
Jackson DB, Sood AK. Personalized cancer medicine-advances and socio-economic challenges. Nat Rev Clin Oncol 2011 ; 8 : 735–741. [CrossRef] [PubMed] [Google Scholar]
Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009 ; 101 : 1044–1048. [CrossRef] [PubMed] [Google Scholar]
Meropol NJ, Schrag D, Smith TJ, et al. American society of clinical oncology guidance statement: the cost of cancer care. J Clin Oncol 2009 ; 27 : 3868–3874. [CrossRef] [PubMed] [Google Scholar]
Les tests de génétique moléculaire pour l’accès aux thérapies ciblées. Collection Rapports et synthèses. Boulogne-Billancourt : INCa, 2010. [Google Scholar]
De Lima Lopes G Jr, Segel JE, Tan DS, et al. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 2011 ; 26 juillet. doi : 10.1002/cncr.26372. [Google Scholar]
Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 2011 ; 17 : 6338–6346. [CrossRef] [PubMed] [Google Scholar]
Shankaran V, Bentrem DJ, Mulcahy MF, et al. Economic implications of KRAS testing in metastatic colorectal cancer. San Francisco, CA : Gastrointestinal Cancers Symposium, January 15–17, 2009. [Google Scholar]
Van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 ; 415 : 530–536. [CrossRef] [PubMed] [Google Scholar]
Van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999–2009. [CrossRef] [PubMed] [Google Scholar]
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 2817–2826. [CrossRef] [PubMed] [Google Scholar]
Bertucci F, Borie N, Roché H, et al. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2011 ; 127 : 363–373. [CrossRef] [PubMed] [Google Scholar]
Marino P, Siani C, Bertucci F, et al. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. Breast Cancer Res Treat 2011 ; 129 : 401–409. [CrossRef] [PubMed] [Google Scholar]
Seror V, Elasri K, Avenel E. Premières applications de la pharmacogénomique en oncologie : stratégies industrielles et enjeux de régulation publique. Revue d’Économie Industrielle 2007 ; 120 : 235–252. [Google Scholar]
Gabszewicz J, Sonnac N, Wauthy X. On price competition with complementary goods. Economics Letters 2001 ; 70 : 431–439. [CrossRef] [Google Scholar]
Bertucci F, Birnbaum D. Génomique et recherche clinique en cancérologie mammaire. Med Sci (Paris) 2012 ; 28 (Suppl 1) : 14–18. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] L’Horty Y, Quinet A, Rupprecht F. Expliquer la croissance des dépenses de santé : le rôle du niveau de vie et du progrès technique. Économie et Prévision 1997 ; 129–130 : 257–268. [Google Scholar]

[2] Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011 ; 103 : 117–128. [CrossRef] [PubMed] [Google Scholar]

[3] Situation de la chimiothérapie des cancers en 2010. Collection Rapports et synthèses. Boulogne-Billancourt : INCa, 2010. [Google Scholar]

[4] Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 2009 ; 27 : 5868–5873. [CrossRef] [PubMed] [Google Scholar]

[5] Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of Bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2009 ; 29 : 1247–1251. [CrossRef] [Google Scholar]

[6] Hensley ML. Big costs for little gain in ovarian cancer. J Clin Oncol 2011 ; 29 : 1230–1232. [CrossRef] [PubMed] [Google Scholar]

[7] Munro AJ, Niblock PG. Cancer research in the global village. Lancet 2010 ; 376 : 659–660. [CrossRef] [PubMed] [Google Scholar]

[8] Jackson DB, Sood AK. Personalized cancer medicine-advances and socio-economic challenges. Nat Rev Clin Oncol 2011 ; 8 : 735–741. [CrossRef] [PubMed] [Google Scholar]

[9] Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009 ; 101 : 1044–1048. [CrossRef] [PubMed] [Google Scholar]

[10] Meropol NJ, Schrag D, Smith TJ, et al. American society of clinical oncology guidance statement: the cost of cancer care. J Clin Oncol 2009 ; 27 : 3868–3874. [CrossRef] [PubMed] [Google Scholar]

[11] Les tests de génétique moléculaire pour l’accès aux thérapies ciblées. Collection Rapports et synthèses. Boulogne-Billancourt : INCa, 2010. [Google Scholar]

[12] De Lima Lopes G Jr, Segel JE, Tan DS, et al. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 2011 ; 26 juillet. doi : 10.1002/cncr.26372. [Google Scholar]

[13] Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 2011 ; 17 : 6338–6346. [CrossRef] [PubMed] [Google Scholar]

[14] Shankaran V, Bentrem DJ, Mulcahy MF, et al. Economic implications of KRAS testing in metastatic colorectal cancer. San Francisco, CA : Gastrointestinal Cancers Symposium, January 15–17, 2009. [Google Scholar]

[15] Van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 ; 415 : 530–536. [CrossRef] [PubMed] [Google Scholar]

[16] Van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999–2009. [CrossRef] [PubMed] [Google Scholar]

[17] Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 2817–2826. [CrossRef] [PubMed] [Google Scholar]

[18] Bertucci F, Borie N, Roché H, et al. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2011 ; 127 : 363–373. [CrossRef] [PubMed] [Google Scholar]

[19] Marino P, Siani C, Bertucci F, et al. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. Breast Cancer Res Treat 2011 ; 129 : 401–409. [CrossRef] [PubMed] [Google Scholar]

[20] Seror V, Elasri K, Avenel E. Premières applications de la pharmacogénomique en oncologie : stratégies industrielles et enjeux de régulation publique. Revue d’Économie Industrielle 2007 ; 120 : 235–252. [Google Scholar]

[21] Gabszewicz J, Sonnac N, Wauthy X. On price competition with complementary goods. Economics Letters 2001 ; 70 : 431–439. [CrossRef] [Google Scholar]

[22] Bertucci F, Birnbaum D. Génomique et recherche clinique en cancérologie mammaire. Med Sci (Paris) 2012 ; 28 (Suppl 1) : 14–18. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]